BellBrook Labs this week announced the launch of its Transcreener ADP2 assay. According to the company, this "next-generation" ADP detection assay offers improved sensitivity and increased flexibility over its original ADP detection assay.
BellBrook Labs said that it has developed an improved monoclonal antibody that allows more sensitive ADP detection and increases the total assay signal. The improved sensitivity and increased signal mean that scientists can get an assay window of Z’ ≥ 0.7, using ATP concentrations as low as 100.0 nM or as high as 1.0 mM under initial velocity conditions (≤10 percent substrate conversion).
Transcreener assays are available for ADP, GDP, UDP, AMP, and GMP detection.
Millipore this week announced the launch of six new flow cytometry kits for stem cell research. The three-parameter FlowCellect kits are designed to help scientists assess embryonic and neural stem cell phenotypes at various stages of differentiation.
In March of this year, Millipore and Hayward, Calif.-based Guava Technologies announced a long-term partnership to deliver integrated flow cytometry solutions to scientists conducting research in cell biology, including stem cell research (see CBA News, 3/7/08). These new stem cell kits are the first developed by Millipore’s research team in Temecula, Calif.